Aptose Biosciences Inc. Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Note 13 - Finance Income and Expense

Note 13 - Finance Income and Expense

12 Months Ended

Dec. 31, 2017

Statement Line Items [Line Items]

Disclosure of finance income (cost) [text block]

13.	Finance income and expense:

Components of finance income:

		Year ended December 31, 2017				Year ended December 31, 2016				Year ended December 31, 2015
						(as recast – note 3 (b))				(as recast – note 3 (b))

Interest income		$	68			$	79			$	226
Foreign exchange gain on cash and cash equivalents			97				-				954
		$	165			$	79			$	1,180

Components of finance expense:

		Year ended December 31, 2017				Year ended December 31, 2016				Year ended December 31, 2015
						(as recast – note 3 (b))				(as recast – note 3 (b))

Interest expense		$	-			$	-			$	21
Accretion expense			-				-				13
Foreign exchange loss on cash and cash equivalents			-				46				-
		$	-			$	46			$	34